¡Ya estamos en ! Descubre más
GLS

Gelesis Holdings, Inc.

Excluida de cotización

GLS dejó de cotizar en bolsa el 10 de abril de 2023.

 

Acerca de: Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Empleados: 93

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre GLS.

Gráficos de precios implementados con Lightweight Charts™